Month: March 2026

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. “We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors. We are on track to provide Phase 1a interim...

Revenue Growth Driving Group to Record EBITDA• Revenue of $186.5 million with organic revenue growth of 6.2%• Record Adjusted EBITDA of $45.4 million, up 17.7% year over year, achieved at a margin of 24.3%• Successfully completed our $45.8 million IPO in the US and dual-listing on Nasdaq in January 2026• Net Debt of $26.6 million has reverted to a Net Cash position in 2026• Completed two acquisitions in 2025, further expanding PPHC’s capabilities and geographic reach   WASHINGTON, March 23, 2026 (GLOBE NEWSWIRE) — Public Policy Holding Company, Inc. (“PPHC,” “Company,” “Group”) (Nasdaq: PPHC and AIM: PPHC.L), a leading global strategic communications provider offering a comprehensive range of advisory services in the areas of Government Relations, Corporate Communications,...

A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years  Cash and cash equivalents surge 120% to $19.1 million following $12.6 million in 2025 warrants exercise and equity raises With revenues up year-over-year at $3.4 million, monthly operating cash burn was cut by 41% to ~$159K — lowest in Company history — with zero-debt on balance sheet Launch of industry-first Secured Autonomy™ cybersecurity framework, multiple new design wins across Europe, Middle East and South Asia, and expanded U.S. Tier-1 drone production-scale orders drive multi-market momentum Webcast scheduled for 4:30 pm EST today PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider...

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update. Business...

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC dual-payload program enters the clinic; patient dosing underway – – Cash, cash equivalents and marketable securities as of December 31, 2025 of $141.4 million, excluding proceeds from the recent capital raise of approximately $110 million which extended cash runway into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),...

Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano. “Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM workflows to potentially thousands of samples per year – to the continued expansion...

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; further guidance on the program expected in Q2 2026 Clinical and preclinical data from ARD-101 program published in Molecular Metabolism  $110.0 million in cash, cash equivalents and short-term investments as of December 31, 2025, supports projected operations into the second quarter of 2027 SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways...

Abivax Announces Full Year 2025 Financial Results and Provides Business UpdatesABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trial The Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026 Abivax appointed Michael Nesrallah, MBA as Chief Commercial Officer, bringing extensive IBD leadership experience to support the Company’s next phase of growth; other key senior leadership hires made in Regulatory Affairs and Research to support continued advancements of its programs Cash, cash equivalents and short-term investments of €530.4M...

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) — Quadravest Preferred Split Share ETF (“Preferred ETF”) announces that its annual financial statements and management report of fund performance for the year ended December 31, 2025 are now available at www.sedarplus.com and Preferred ETF’s website at www.quadravest.com. For further information, please contact Investor Relations at 416-304-4443, toll free at 1-877-4-Quadra (1-877-478-2372), or visit www.quadravest.com.